Abiopharma

🔍 Krempa David (Executive)

Company: Eton Pharmaceuticals, Inc. (ETON)

Report Date: 2026-01-12

Detailed Transactions and Holdings:

• Sold 1,942 shares of Common Stock at $15.62 per share (Direct)
  Date: 2026-01-14 | Code: F | equity_swap_involved: 0 | shares_owned_after: 630,238.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 40,655 shares of Employee Stock Option (Right to Buy) at $15.47 per share (Derivative)
  Date: 2026-01-12 | Code: A | Expires: 2036-01-11 | equity_swap_involved: 0 | shares_owned_after: 670,893.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 25,856 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-12 | Code: A | equity_swap_involved: 0 | shares_owned_after: 696,749.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
• F2: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
• F3: The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
• F4: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
• F5: The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.
• REMARKS: The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.